Acumen Pharmaceuticals, Inc. (ABOS) Social Stream
ACUMEN PHARMACEUTICALS INC (ABOS) Price Targets From Analysts
Use the tables below to see what analysts covering ACUMEN PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-17 | 3 | $27 | $20 | $24.666 | $3.87 | 537.36% |
| 2021-11-19 | 3 | $27 | $16 | $23.333 | $3.87 | 502.92% |
| 2022-01-21 | 3 | $27 | $14 | $22.666 | $3.87 | 485.68% |
| 2022-03-07 | 3 | $27 | $14 | $19.333 | $3.87 | 399.56% |
| 2022-05-27 | 3 | $27 | $9 | $17.666 | $3.87 | 356.49% |
| 2022-07-15 | 5 | $17 | $9 | $14 | $3.87 | 261.76% |
| 2022-08-13 | 3 | $17 | $9 | $14 | $3.87 | 261.76% |
| 2022-11-18 | 4 | $17 | $9 | $14 | $3.87 | 261.76% |
| 2023-03-28 | 4 | $22.001 | $9 | $15.75 | $3.87 | 306.98% |
| 2023-05-12 | 4 | $22.001 | $9 | $15 | $3.87 | 287.6% |
| 2023-07-06 | 5 | $22.001 | $9 | $14.6 | $3.87 | 277.26% |
| 2023-08-09 | 5 | $22.001 | $13 | $16.2 | $3.87 | 318.6% |
| 2023-10-04 | 5 | $17 | $13 | $14.75 | $3.87 | 281.14% |
| 2023-11-14 | 4 | $17 | $14 | $15.333 | $3.87 | 296.2% |
| 2023-12-29 | 5 | $17 | $8 | $13.5 | $3.87 | 248.84% |
The Trend in the Analyst Price Target
Over the past 17 months, ABOS's average price target has gone down $0.5.
ABOS reports an average of 258.59% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-08-09 | 5 | 22.001 | 13 | 16.200 | 6.78 | 138.94% |
| 2023-10-04 | 5 | 17.000 | 14 | 15.333 | 4.17 | 267.7% |
| 2023-11-14 | 4 | 17.000 | 14 | 15.333 | 2.13 | 619.86% |
| 2023-12-22 | 5 | 17.000 | 8 | 13.500 | 3.57 | 278.15% |
| 2023-12-29 | 5 | 17.000 | 8 | 13.500 | 3.84 | 251.56% |
ABOS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 26 weeks, ABOS's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In the context of all US stocks, ACUMEN PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 1819.17% of them.
- In the context of all US stocks, ACUMEN PHARMACEUTICALS INC's number of analysts covering the stock is higher than 273.25% of them.
- In the context of all US stocks, ACUMEN PHARMACEUTICALS INC's average analyst price target is greater than 405.69% of them.
- ACUMEN PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1165.44% of stocks in the small market cap category.
In the Pharmaceutical Products industry, SOPH, CADL, and ICVX are the three stocks most similar to ACUMEN PHARMACEUTICALS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for ABOS? Use POWR Ratings for clearer insight into price direction.